Investing in Bacterial Vaccine R&D to Combat AMR
New Publication in Vaccine!
Vaccines play a vital role in preventing infections and reducing antibiotic use, making them essential tools in the fight against antimicrobial resistance (AMR). Given that AMR disproportionately impacts Low- and Middle-Income Countries (LMICs), this study provides this first comprehensive analysis of global investments in bacterial vaccine research and development (R&D) in LMICs.
Publicly available funding data from the G-FINDER and Global AMR R&D Hub databases, were examined, covering projects active between January 2007 and January 2024. The study identifies funding recipients, geographic distribution, and the role of intermediary organizations in bacterial vaccine R&D.
Key Findings
- $4.5 billion invested globally in bacterial vaccine R&D, primarily targeting M. tuberculosis and S. pneumoniae.
- Most funding was allocated to organizations in North America and Europe, while Asia, Africa, and Central/South America collectively received less than 20%.
- Philanthropic and intermediary organizations, particularly Product Development Partnerships (PDPs), play a critical role in channeling funds to LMICs and advancing vaccine development.
Looking Ahead
Transparent reporting is essential to accurately track funding flows to LMICs. While PDPs and intermediary funders are instrumental in bridging investment gaps, significant funding shortfalls remain for key bacterial pathogens on WHO’s bacterial priority pathogen list. Strengthening global collaboration and targeted investments will be crucial in addressing these gaps and ensuring equitable vaccine development.